Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Voorraadrapport

Marktkapitalisatie: US$7.2b

Jazz Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Jazz Pharmaceuticals is Bruce Cozadd, benoemd in Jan2003, heeft een ambtstermijn van 21.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.34M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.52% van de aandelen van het bedrijf, ter waarde $ 37.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.2 jaar en 11.5 jaar.

Belangrijke informatie

Bruce Cozadd

Algemeen directeur

US$15.3m

Totale compensatie

Percentage CEO-salaris7.8%
Dienstverband CEO21.8yrs
Eigendom CEO0.5%
Management gemiddelde ambtstermijn5.2yrs
Gemiddelde ambtstermijn bestuur11.5yrs

Recente managementupdates

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Recent updates

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Nov 18

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Analyse CEO-vergoeding

Hoe is Bruce Cozadd's beloning veranderd ten opzichte van Jazz Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$463m

Jun 30 2024n/an/a

US$395m

Mar 31 2024n/an/a

US$331m

Dec 31 2023US$15mUS$1m

US$415m

Sep 30 2023n/an/a

US$80m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$156m

Dec 31 2022US$17mUS$1m

-US$224m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$450m

Dec 31 2021US$16mUS$1m

-US$330m

Sep 30 2021n/an/a

-US$161m

Jun 30 2021n/an/a

US$40m

Mar 31 2021n/an/a

US$518m

Dec 31 2020US$13mUS$1m

US$239m

Sep 30 2020n/an/a

US$179m

Jun 30 2020n/an/a

US$133m

Mar 31 2020n/an/a

US$280m

Dec 31 2019US$15mUS$1m

US$523m

Sep 30 2019n/an/a

US$609m

Jun 30 2019n/an/a

US$656m

Mar 31 2019n/an/a

US$486m

Dec 31 2018US$11mUS$979k

US$447m

Sep 30 2018n/an/a

US$520m

Jun 30 2018n/an/a

US$434m

Mar 31 2018n/an/a

US$447m

Dec 31 2017US$10mUS$950k

US$488m

Compensatie versus markt: De totale vergoeding ($USD 15.34M ) Bruce } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.94M ).

Compensatie versus inkomsten: De vergoeding van Bruce is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bruce Cozadd (60 yo)

21.8yrs

Tenure

US$15,341,235

Compensatie

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Bruce Cozadd
Co-Founder21.8yrsUS$15.34m0.52%
$ 37.6m
Renee Gala
President & COO1.1yrsUS$5.43m0.028%
$ 2.0m
Patricia Carr
Senior VP & Chief Accounting Officer5.3yrsUS$1.40mgeen gegevens
Neena Patil
Executive VP & Chief Legal Officer5.3yrsUS$3.88m0.012%
$ 879.4k
Robert Iannone
Executive VP5.5yrsUS$4.98m0.047%
$ 3.4m
Philip Johnson
Executive VP & CFOless than a yeargeen gegevens0.020%
$ 1.4m
Andrea Flynn
VP & Head of Investor Relationsno datageen gegevensgeen gegevens
Heidi Manna
Executive VP & Chief People Officer6yrsgeen gegevensgeen gegevens
Jed Black
Senior Vice President of Sleep & CNS Medicineno datageen gegevensgeen gegevens
Samantha Pearce
Executive VP & Chief Commercial OfficerChief Commercial Officer4.7yrsgeen gegevens0.011%
$ 763.4k
John Miller
Senior Vice President of Corporate Strategy5.2yrsgeen gegevensgeen gegevens
Mary Henderson
Senior Vice President of Technical Operations1.3yrsgeen gegevens0.0021%
$ 152.8k

5.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van JAZZ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Bruce Cozadd
Co-Founder21.8yrsUS$15.34m0.52%
$ 37.6m
Kenneth O'Keefe
Independent Director20.8yrsUS$513.77k0.046%
$ 3.3m
Seamus Mulligan
Independent Director12.8yrsUS$531.27k1.93%
$ 139.4m
Norbert Riedel
Independent Director11.5yrsUS$533.77k0.020%
$ 1.5m
Patrick Gerald Enright
Independent Director15.3yrsUS$526.27k0.035%
$ 2.5m
Patrick Kennedy
Independent Directorless than a yeargeen gegevensgeen gegevens
Rick Winningham
Lead Independent Director14.5yrsUS$571.27k0.015%
$ 1.1m
Jennifer Cook
Independent Non-Executive Director3.9yrsUS$533.77k0.0089%
$ 644.4k
Laura Hamill
Independent Directorless than a yeargeen gegevens0.0025%
$ 178.8k
Heather McSharry
Independent Director11.5yrsUS$543.77k0.025%
$ 1.8m
Mark Smith
Independent Non-Executive Director3.9yrsUS$521.27k0.0089%
$ 644.4k
Anne O'Riordan
Independent Director5.8yrsUS$523.77k0.018%
$ 1.3m

11.5yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van JAZZ zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.5 jaar).